JW PHARMACEUTICAL
Financials
Valuation Metrics
JW PHARMACEUTICAL's Market Cap is ₩5568B. At end of 2025 it was ₩6166B. Ranked #406 of 2,436 in KR market (top 17%), #271 of 787 on KOSPI (top 34%), #46 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 556.83B KRW | KR#406/2,436 Sec#46/234 |
| Revenue | 789.95B KRW | KR#458/2,436 Sec#20/234 |
| Net Income | 71.52B KRW | KR#285/2,436 Sec#19/234 |
| Total Assets | 621.61B KRW | KR#648/2,436 Sec#36/234 |
| Net Assets | 381.78B KRW | KR#592/2,436 Sec#38/234 |
| Employees | 1,107 | KR#237/2,436 Sec#14/234 |
| Value | ||
| P/E | 7.79x | KR#546/2,436 Sec#25/234 |
| P/B | 1.46x | KR#1,767/2,436 Sec#126/234 |
| PEG | 0.14x | KR#444/2,436 Sec#24/234 |
| P/S | 0.70x | KR#1,157/2,436 Sec#59/234 |
| EV/EBITDA | 5.36x | KR#262/2,436 Sec#6/234 |
| FCF Yield | 15.20% | KR#459/2,436 Sec#12/234 |
| Profitability | ||
| ROE | 18.73% | KR#153/2,436 Sec#10/234 |
| ROA | 11.51% | KR#144/2,436 Sec#13/234 |
| Op. Margin | 13.42% | KR#326/2,436 Sec#29/234 |
| Revenue Growth | 7.91% | KR#1,028/2,436 Sec#95/234 |
| Earnings Growth | 57.31% | KR#535/2,436 Sec#29/234 |
| Financial Health | ||
| Debt Ratio | 162.82% | KR#1,352/2,436 Sec#155/234 |
| Total Debt | 32.10B KRW | KR#1,165/2,436 Sec#90/234 |
| FCF | 84.62B KRW | KR#218/2,436 Sec#13/234 |
| Cash | 20.55B KRW | KR#1,222/2,436 Sec#90/234 |
| Current Ratio | 1.46x | KR#1,337/2,436 Sec#146/234 |
| Net Debt/EBITDA | 0.11x | KR#702/2,436 Sec#46/234 |
| Dividend | ||
| Div. Yield | 2.80% | KR#707/2,436 Sec#37/234 |
| Div. Growth | 44.44% | KR#260/2,436 Sec#11/234 |
| Performance | ||
| 1Y Return | 8.76% | KR#552/2,436 Sec#43/234 |
| 1M Return | -6.38% | KR#1,510/2,436 Sec#153/234 |
| From 52W High | -38.34% | KR#686/2,436 Sec#48/234 |
| 1Y MDD | -43.66% | KR#651/2,436 Sec#52/234 |
| Trading | ||
| Volume | 28,236 shares | KR#1,681/2,436 Sec#167/234 |
| Foreign Own. | 8.97% | KR#514/2,436 Sec#43/234 |
| Per Share | ||
| EPS | 2,872 KRW | KR#289/2,436 Sec#18/234 |
| BPS | 15,804 KRW | KR#622/2,436 Sec#40/234 |
Company Info
The company began as Joseon Choongwae Pharmaceutical Laboratory in 1945, incorporated in 1953, and expanded its business in 2019 by acquiring Vietnamese Euvipharm after listing in 1976. It holds products such as Livalo, Hemlibra, Trupass, Actemra, and the 3rd-generation 3-chamber nutritional infusion Winuf. The company leads the market with its combined novel drug of pitavastatin and ezetimibe. Utilizing the JWAVE platform, it applies AI models across the entire new drug development cycle to reduce time and cost. JW Pharmaceutical is headquartered in Gwacheon, Gyeonggi-do.